Join NervGen Pharma Corp. for a virtual investor event featuring key opinion leaders (KOL) Monica Perez, PT, PhD (Northwestern University) and Steven Kirshblum, MD (Kessler Institute for Rehabilitation), who will join company management to discuss the unmet medical need and current treatment landscape for individuals with spinal cord injury.

Ahead of clinical data expected in the second quarter for its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial, the event will highlight the study design and overview of electrophysiology. Company management will also overview data from preclinical trials evaluating NVG-291-R and the Phase 1 trial evaluating safety of NVG-291, NervGen’s first-in-class therapeutic peptide targeting nervous system repair, in chronic and subacute SCI.

A live question and answer session will follow the formal presentations.